(Q46360951)

English

Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

author name string

T Sawada

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

T Takahashi

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

H Yamada

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

B Dahlöf

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

H Matsubara

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

KYOTO HEART Study Group

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

publication date

18 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

Journal of Human Hypertension

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

23

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

188-195

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

Angiotensin-Converting Enzyme Inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

21 January 2018

Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

21 January 2018

World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Beneficial effect of angiotensin II type 1 receptor blocker antihypertensive treatment on arterial stiffness: the role of smoking

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the management of hypertension for general practitioners

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Statistics in medicine--reporting of subgroup analyses in clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/JHH.2008.116

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18800142

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46360951&oldid=2207817936"